冠心丹参滴丸联合西药治疗冠心病初发型心绞痛气滞血瘀证临床研究  

Clinical Study on Guanxin Danshen Dripping Pills Combined with Western Medicine for Initial Angina of Coronary Heart Disease with Qi Stagnation and Blood Stasis Syndrome

作　　者：张静[1] 舒荣华 李华文 ZHANG Jing;SHU Ronghua;LI Huawen

机构地区：[1]上海交通大学医学院附属瑞金医院舟山分院心内科,浙江舟山316012

出　　处：《新中医》2023年第4期46-50,共5页New Chinese Medicine

摘　　要：目的:观察冠心丹参滴丸联合西药治疗冠心病初发型心绞痛气滞血瘀证的临床疗效。方法:选取120例冠心病初发型心绞痛气滞血瘀证患者,以随机数字表法分为对照组和治疗组各60例。对照组给予单硝酸异山梨酯片、阿司匹林片治疗,突发心绞痛时服用硝酸甘油片,治疗组在对照组基础上给予冠心丹参滴丸治疗,2组均治疗8周。比较2组临床疗效,观察2组治疗前后中医证候评分、血清P选择素(Ps)和内皮素-1(ET-1)水平及心功能指标[心输出量(CO)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)及心脏指数(CI)]的变化。结果:治疗后,治疗组临床疗效总有效率96.67%,高于对照组85.00%(P<0.05)。2组胸痛、胸闷、胸胁胀满、心悸评分及总分均较治疗前降低(P<0.05),治疗组胸痛、胸闷、胸胁胀满、心悸评分及总分均低于对照组(P<0.05)。2组血清Ps、ET-1水平均较治疗前降低(P<0.05),治疗组血清Ps、ET-1水平均低于对照组(P<0.05)。2组CO、LVEF及CI值均较治疗前升高(P<0.05),治疗组CO、LVEF及CI值均高于对照组(P<0.05);2组LVEDD均较治疗前缩小(P<0.05),治疗组LVEDD小于对照组(P<0.05)。结论:冠心丹参滴丸联合西药治疗冠心病初发型心绞痛气滞血瘀证疗效满意,可有效缓解患者的临床症状,改善血管内皮功能,保护心功能。Objective:To observe the clinical effect of Guanxin Danshen Dripping Pills combined with western medicine on initial angina of coronary heart disease with qi stagnation and blood stasis syndrome.Methods:A total of 120 cases with initial angina of coronary heart disease with qi stagnation and blood stasis syndrome were selected and divided into the control group and the treatment group according to the random number table method,with 60 cases in each group.The control group was treated with Isosorbide Mononitrate Tablets and Aspirin Tablets,treat with Nitroglycerin Tablets in case of coronary heart disease,and the treatment group was additionally given Guanxin Danshen Dripping Pills based on the treatment of the control group.The two groups were treated for 8 weeks.The clinical effects in both groups were compared.Before and after treatment,the changes of traditional Chinese medicine(TCM)syndrome scores,levels of serum P-selectin(Ps)and endothelin-1(ET-1)in serum,as well as the heart function indexes[the cardiac output(CO),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),cardiac index(CI)]in both groups were observed.Results:After treatment,The total effective rate was 96.67% in the treatment group,higher than that of 85.00% in the control group(P<0.05).The scores of chest pain,chest distress,hypochondrium and palpitation and fullness in chest as well as the total score in both groups were decreased when compared with those before treatment(P<0.05),and the four scores above as well as the total score in the treatment group were lower than those in the control group(P<0.05).Compared with those before treatment,the levels of Ps and ET-1 in serum in the two groups were decreased(P<0.05),and the two levels above in the treatment group were lower than those in the control group(P<0.05).The CO,LVEF and CI in both groups were increased when compared with those before treatment(P<0.05),and the CO,LVEF and CI in the treatment group were higher than those in the control group(P<0.05);L

关 键 词：冠心病 初发型心绞痛 气滞血瘀证 冠心丹参滴丸 P选择素 内皮素-1 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]